{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:40:04Z","timestamp":1794663604211,"version":"4.9.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CD008748"],"award-info":[{"award-number":["P30 CD008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bneo.2024.100031","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T12:08:02Z","timestamp":1722427682000},"page":"100031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas"],"prefix":"10.1016","volume":"1","author":[{"given":"Paola","family":"Ghione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt S.","family":"Bantilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7883-289X","authenticated-orcid":false,"given":"Erel","family":"Joffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-4898","authenticated-orcid":false,"given":"Ariela","family":"Noy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9500-1804","authenticated-orcid":false,"given":"Paul","family":"Hamlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1381-5810","authenticated-orcid":false,"given":"Anita","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4581-3721","authenticated-orcid":false,"given":"Matthew","family":"Matasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Falchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Straus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-5256","authenticated-orcid":false,"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1403-6883","authenticated-orcid":false,"given":"Andrew D.","family":"Zelenetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bneo.2024.100031_bib1","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.bneo.2024.100031_bib2","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMra2102568","article-title":"Marginal-zone lymphomas","volume":"386","author":"Rossi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.bneo.2024.100031_bib3","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2024.100031_bib4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/sj.leu.2405068","article-title":"Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria","volume":"22","author":"Matutes","year":"2008","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bneo.2024.100031_bib5","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/PAS.0b013e318271243d","article-title":"Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology?","volume":"36","author":"Ponzoni","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.bneo.2024.100031_bib6","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1309\/AJCPEMVXES72DUIF","article-title":"Clinicopathologic features of CD5-positive nodal marginal zone lymphoma","volume":"140","author":"Jaso","year":"2013","journal-title":"Am J Clin Pathol"},{"issue":"13","key":"10.1016\/j.bneo.2024.100031_bib7","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1182\/blood-2002-05-1525","article-title":"Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production","volume":"100","author":"Gary-Gouy","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2024.100031_bib8","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood.V99.3.815","article-title":"De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients","volume":"99","author":"Yamaguchi","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2024.100031_bib9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/ejh.12847","article-title":"Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH","volume":"98","author":"Thakral","year":"2017","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/j.bneo.2024.100031_bib10","doi-asserted-by":"crossref","first-page":"e782","DOI":"10.1016\/j.clml.2020.05.003","article-title":"De novo CD5(+) diffuse large B-cell lymphoma: biology, mechanism, and treatment advances","volume":"20","author":"Xu","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bneo.2024.100031_bib11","article-title":"CD5 gene signature identifies diffuse large B-cell lymphomas sensitive to Bruton's tyrosine kinase inhibition","volume":"42","author":"Cooper","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.bneo.2024.100031_bib12","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bneo.2024.100031_bib13","first-page":"1","article-title":"New directions for mantle cell lymphoma in 2022","volume":"42","author":"Kumar","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"10.1016\/j.bneo.2024.100031_bib14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9873","key":"10.1016\/j.bneo.2024.100031_bib15","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bneo.2024.100031_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/bjh.14228","article-title":"Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era","volume":"175","author":"Starr","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.bneo.2024.100031_bib17","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00277-013-1900-4","article-title":"Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma","volume":"93","author":"Olszewski","year":"2014","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.bneo.2024.100031_bib18","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2018-02-833608","article-title":"Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance","volume":"132","author":"Kalpadakis","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2024.100031_bib19","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bjh.15641","article-title":"Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA\/IELSG36 study","volume":"183","author":"Iannitto","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.bneo.2024.100031_bib20","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/ajh.25707","article-title":"Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma","volume":"95","author":"Olszewski","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bneo.2024.100031_bib21","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.2147\/CMAR.S267258","article-title":"Chemotherapy-free management of follicular and marginal zone lymphoma","volume":"13","author":"Ollila","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.bneo.2024.100031_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/10428194.2021.1973670","article-title":"CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine\/rituximab","volume":"63","author":"Hsu","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.bneo.2024.100031_bib23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/aje\/kwp107","article-title":"Competing risk regression models for epidemiologic data","volume":"170","author":"Lau","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"11","key":"10.1016\/j.bneo.2024.100031_bib24","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risks and multi-state models","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"issue":"446","key":"10.1016\/j.bneo.2024.100031_bib25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"12","key":"10.1016\/j.bneo.2024.100031_bib26","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","article-title":"A\u00a0MALT lymphoma prognostic index","volume":"130","author":"Thieblemont","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bneo.2024.100031_bib27","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1182\/blood-2010-02-267476","article-title":"Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group","volume":"116","author":"Salido","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2024.100031_bib28","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3324\/haematol.2009.011049","article-title":"CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases","volume":"95","author":"Baseggio","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bneo.2024.100031_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106840","article-title":"CD5-positive marginal zone lymphoma: clinicopathological features and survival outcomes","volume":"117","author":"Xia","year":"2022","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.bneo.2024.100031_bib30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/asheducation-2017.1.329","article-title":"The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment","volume":"2017","author":"Gaidano","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"20","key":"10.1016\/j.bneo.2024.100031_bib31","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features","volume":"72","author":"Navarro","year":"2012","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.bneo.2024.100031_bib32","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/10428194.2022.2148218","article-title":"Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection","volume":"64","author":"Bantilan","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.bneo.2024.100031_bib33","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2024.100031_bib34","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:53:06Z","timestamp":1756255986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328024000311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2950328024000311"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100031","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100031"}}